Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Free Report) CEO Stephen R. Brady bought 35,000 shares of the stock in a transaction on Wednesday, July 3rd. The shares were acquired at an average cost of $2.11 per share, for a total transaction of $73,850.00. Following the completion of the transaction, the chief executive officer now directly owns 46,376 shares of the company’s stock, valued at $97,853.36. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Tempest Therapeutics Stock Performance
Tempest Therapeutics stock opened at $2.15 on Thursday. Tempest Therapeutics, Inc. has a 12 month low of $0.17 and a 12 month high of $9.77. The stock has a market cap of $47.77 million, a price-to-earnings ratio of -1.25 and a beta of -1.73. The business has a 50 day moving average price of $2.92 and a two-hundred day moving average price of $3.55. The company has a quick ratio of 3.13, a current ratio of 3.13 and a debt-to-equity ratio of 0.20.
Tempest Therapeutics (NASDAQ:TPST – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.08. As a group, equities analysts forecast that Tempest Therapeutics, Inc. will post -1.57 EPS for the current year.
Hedge Funds Weigh In On Tempest Therapeutics
Analyst Ratings Changes
A number of research firms recently issued reports on TPST. Scotiabank initiated coverage on shares of Tempest Therapeutics in a research note on Thursday, March 14th. They issued a “sector outperform” rating and a $13.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $47.00 price target on shares of Tempest Therapeutics in a research report on Thursday, June 20th. William Blair reissued an “outperform” rating on shares of Tempest Therapeutics in a research report on Wednesday, March 20th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $8.00 target price on shares of Tempest Therapeutics in a report on Friday, June 21st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $20.75.
Check Out Our Latest Analysis on Tempest Therapeutics
Tempest Therapeutics Company Profile
Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.
Recommended Stories
- Five stocks we like better than Tempest Therapeutics
- What is a SEC Filing?
- This Stock’s Price Shifts Into High Gear With Analyst Upgrades
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- AI Boosts Glass Tech Leader Stock: Shares Up 75% and More to Come
- Basic Materials Stocks Investing
- AI Partnership Boosts This Top Tech Stock: Ready for More Gains?
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.